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Despite a century of intensive biologi-
cal and pharmacological research result-
ing in hundreds of new drugs and clinical 
trials, the only curative therapy of most 
solid tumors remains surgery of localized 
disease. Once metastatic cells have left pri-
mary tumors and have hidden in protective 
niches or nidated in distant organs, patients 
will eventually experience recurrence and 
finally death. Physical agents used in radi-
otherapy may delay regional spreading 
whereas chemical agents used in chemo-
therapies may induce tumor shrinking but 
rarely totally eradicate cancers at a systemic 
stage. In addition, these effects are obtained 
at the price of intense toxicity which ham-
pers the treatment of older patients, at an 
age when most cancers occur. Targeted 
therapies, interfering with pathways criti-
cal for the cancer cells, which have proven 
efficacy in hematological malignancies, are 
still in their infancy for solid tumors and it 
becomes now evident that cancer cells are 
capable to develop escape mechanisms to 
this new class of drugs.
Immunotherapies have been for a long 
time a matter of hopes and disillusions. In 
the recent years, however, they have begun 
to gain their place among the therapeutic 
arsenal of cancer therapies. They are classi-
cally thought to work through two mecha-
nisms, the first the direct destruction of 
tumor cells, the second indirect anti-can-
cer effects via stimulation of the immune 
system. The destruction of tumor cells 
can be achieved by monoclonal antibodies 
which recruit effector NK cells and mac-
rophages and possibly neutrophils to the 
tumor through their Fc portion, and trigger 
their Fc receptors resulting in killing of the 
malignant cells (Clynes et al., 1998; Carter, 
2006). Several monoclonal antibodies of 
this type have been approved including 
rituximab (an anti-CD20 antibody) for B 
cell malignancies, cetuximab (an anti-EGF 
receptor antibody) for wild-type Ki-Ras 
colorectal cancer, or trastuzumab (an anti-
HER2/neu antibody) for breast and head 
and neck cancers (Galluzzi et al., in press). 
A direct destruction of tumor cells can 
also be achieved by cellular therapies such 
as the infusion of allogeneic hematologic 
stem cells, from bone marrow or blood, 
approved for the treatment of leukemia 
(Ashfaq et al., 2010) or that of differenti-
ated cytotoxic T cells for the treatment of 
solid tumors, although the latter are still in 
clinical trials (Rosenberg et al., 2011). The 
other approach, immunostimulation of 
the immune system has been historically 
achieved by bacteria or bacterial extracts 
(e.g., the Coley toxin). BCG is still used to 
treat superficial bladder cancer (Finn, 2008; 
Disis, 2010). The modern version of this 
approach of non-specific stimulation is rep-
resented by interleukin 2, which is approved 
for the treatment of metastatic melanoma 
and renal cancer (Rosenberg et al., 1987). 
Therapeutic vaccines have become a reality 
with the approval of Provenge as a treat-
ment for metastatic, hormone refractory 
prostate cancer with autologous dendritic 
cells (DC) pulsed with a prostatic antigen, 
PSMA fused to GM-CSF (Beer et al., 2011; 
Gulley and Drake, 2011). PROSTVAC, a 
therapeutic vaccine for the same disease 
which uses poxvirus as a vector and PSA as 
an antigen, is in advanced stage of clinical 
validation (Kantoff et al., 2010). The most 
promising agents are, again, monoclonal 
antibodies that modulate the immune 
system. Ipilimumab, an anti-CTLA-4 anti-
body which blocks CTLA-4/CD28 interac-
tion and therefore unlocks a lymphocyte 
checkpoint, has recently been approved 
for the treatment of metastatic melanoma 
(Hodi et al., 2010). Anti-PD1 antibodies 
which unlock the PD1/PDL-1 checkpoint 
are being explored in phase II studies 
(Waldmann, 2006; Kline and Gajewski, 
2010; Rosenblatt et al., 2011). Bevacizumab 
(Yang et al., 2003), an antibody which neu-
tralizes VEGF, approved for the treatment 
of colorectal, lung and breast cancers, has 
a dual effect: it decreases the neo-vascu-
larization of tumors but it also blocks the 
maturation-inhibiting activity of VEGF on 
DC, resulting in a decrease in regulatory T 
cells and myeloïd derived suppressor cells, 
and thus acts as an immunomodulatory 
agent (Tartour et al., 2011).
The last decade witnessed the develop-
ment of these new therapies but also the 
achievement of comprehensive analyses of 
the immune microenvironment of human 
tumors that shed light on what components 
of the local immune infiltrate influence 
cancer development and how they impact 
various parameters of patients clinical out-
come. The deepest studies were performed 
in colorectal cancers (Galon et al., 2006; 
Pagès et al., 2010; Fridman et al., 2011a,b; 
Mlecnik et al., 2011; Tosolini et al., 2011) 
and most of the conclusions reached in these 
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striking. Metastatic melanoma sites either 
shrink, or are not modified in size or grow 
during antibody treatment, or even new 
sites appear. The only significant effect is 
an increase of patients overall survival, 
an excellent predictor of this effect being 
again the infiltration of metastatic sites 
by CD8 T cells. Treatment with anti-PD1 
antibodies follows the same rules (Nomi 
et al., 2007). Strikingly, treatment with 
anti-angiogenic agents reveals a similar 
phenomenon. A recently published clini-
cal trial where patients with metastatic 
renal cancer were treated with sunitinib 
(an inhibitor of VEGF receptor signaling) 
with or without bevacizumab (an anti 
VEGF-A antibody) revealed that some of 
them had a decrease in regulatory T cells. 
The patients with decreased Treg had a 
longer survival than the group of patients 
on which Treg decrease was not induced 
(Adotevi et al., 2010). Interestingly, the 
decrease of Treg did not correlate with 
clinical response assessed by Recist cri-
teria but only with overall survival. In 
patients treated with sunitinib in a neo-
adjuvant setting, i.e., before surgery, a 
decrease in intra-tumoral regulatory T 
cells was detected. Finally, it is striking 
that in patients presenting with metastatic 
prostate cancer treated with therapeutic 
vaccines, there was no effect of disease 
progression but only on overall survival 
(Kantoff et al., 2010; Beer et al., 2011; 
Gulley and Drake, 2011). It is tempting 
to speculate that the effect on overall 
(but not progression-free survival is the 
consequence of the induction of an adap-
tive immune response to the vaccine and 
putatively to the tumor.
From these examples, it clearly results 
that these are two important steps should 
be attained by anti-cancer therapies: the 
first one is to reduce the tumor burden by 
surgery, radiotherapy, chemotherapy, or 
anti-tumor antibodies. If some tumor cells 
escape these treatments, the cure of cancer, 
or at least its maintenance in an equilib-
rium stage, is the result of the second step, 
i.e., the induction of an adaptive T cell 
response which may be efficiently sustained 
by immunomodulatory agents.
To reach long-term survival and there-
fore clinical cure of cancerous patients, 
innovative treatments regimen should take 
into account these two steps.
et al., 2007) and P2RX7 (Ghiringhelli et al., 
2009) among other receptors, respectively 
favor processing of tumor antigens and 
Tc1 polarization of CD8+ T lymphocytes 
(Ghiringhelli et al., 2009) allowing for 
the subsequent activation of an adaptive 
immune reaction. Indeed in retrospec-
tive studies, polymorphisms of TLR4 and 
P2RX7 were associated with survival in 
chemotherapy treated patients (Apetoh 
et al., 2007; Ghiringhelli et al., 2009). 
Strikingly, a recent study of DTIC treated 
metastatic melanoma showed that survival 
was indeed correlated, among other fac-
tors, with T cell infiltration in metastases 
(Nardin et al., 2011). In human, high T cell 
infiltration of hepatic metastases of colo-
rectal cancer was a predictor of patient’s 
response to chemotherapy (Halama et al., 
2011). Thus, although drug-induced tumor 
shrinkage is independent of the immune 
reaction, patient survival may be the con-
sequence of the induction/increase of a sus-
tained immune reaction. In line with these 
results, clinical efficacy of radiotherapy also 
required CD8+ T cells, in preclinical mod-
els (Lee et al., 2009).
The analysis of the effects of immuno-
therapies leads to the same conclusion. In 
mouse models, it was demonstrated that 
although the clearance of an autologous 
CD20 positive lymphoma or an HER2 
positive carcinoma by anti-CD20 (Abès 
et al., 2010) and anti-HER2 (Park et al., 
2010) monoclonal antibodies respectively, 
requires NK cells, an equilibrium phase 
is established that involves an antigen-
specific T cell response (Abès et al., 2010; 
Park et al., 2010; Abès and Teillaud, 2011; 
Stagg et al., 2011). A second graft of the 
tumor is rejected in an antigen-specific 
manner, without a second antibody chal-
lenge. If CD4 cells are depleted during the 
treatment with the therapeutic monoclo-
nal antibody (the induction phase) such 
memory is not induced, and if CD8 cells 
are removed prior to the second graft (the 
maintenance phase), it is not rejected (Abès 
et al., 2010). In human, administration of 
anti-HER2/neu monoclonal antibodies 
also induced endogenous anti-HER2/neu 
humoral and cellular immune responses 
(Taylor et al., 2007). Thus, the long-term 
effects of therapeutic anti-tumor antibod-
ies are also mediated by an adaptive T cell 
response (Abès et al., 2010; Park et al., 2010; 
Stagg et al., 2011).
analyses were reported to apply to many 
other tumors, such as ovarian, lung, breast, 
head and neck, prostate, liver, urothelial 
carcinoma, or melanoma (Fridman et al., 
2011b). The main finding was that infiltra-
tion of primary tumors by high numbers 
of memory Th1/cytotoxic T cells both in 
the core (“center”) and the invasive mar-
gin of the tumor nests was associated with 
good clinical outcome (Galon et al., 2006). 
Pro-inflammatory cells (Th-17; Tosolini 
et al., 2011) or cytokines (IL-17, IL-6, etc.; 
Tartour et al., 1996; Tosolini et al., 2011) 
are associated with poor prognosis. The 
case of regulatory T cells is more complex: 
they are associated with poor prognosis 
in ovarian cancer (Curiel et al., 2004) and 
gastrointestinal sarcoma (Balachandran 
et al., 2011), but they constitute a predic-
tor of favorable clinical outcome in head 
and neck (Badoual et al., 2006), colorectal 
cancers (Salama et al., 2009), and Hodgkin 
lymphoma (Carreras et al., 2006). What 
emerges from numerous studies is that, 
even if the density of infiltrating adap-
tive immune cells decreases upon tumor 
spreading (Mlecnik et al., 2011), their main 
impact is on survival of the patients. It thus 
raises the hypothesis that cancer therapies 
with long-term beneficial effects may have 
limited impact on local disease but should 
activate a relevant adaptive immune reac-
tion that will result in control of poten-
tial metastatic spreading and establish an 
homeostasis which allows patients to live 
with a controlled disease.
Pioneering work by Laurence Zitvogel 
and Guido Kroemer, in mouse models, 
revealed that chemotherapy could retard 
the growth of tumors growing on immu-
nocompetent but had no effect on tumors 
established on immunodeficient mice 
(Zitvogel et al., 2008, 2011; Galluzzi et al., 
2011). Based on these results, the con-
cept of immunogenic chemotherapy was 
launched hypothesizing that a drug is cura-
tive if it provokes an immunogenic death 
of the malignant cells, thereby inducing an 
adaptive immune response which clears, or 
maintains dormant, escaping tumor cells. 
The molecular mechanisms of the immu-
nogenic cell death have been deciphered. 
The exposition of calreticulin on the sur-
face of the dying tumor cells increases their 
uptake by DC. DC are also stimulated by 
HMGB1 and ATP released from dying 
tumor cells, which act on TLR4 (Apetoh 
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